Gene interaction enrichment and network analysis to identify dysregulated pathways and their interactions in complex diseases

BackgroundThe molecular behavior of biological systems can be described in terms of three fundamental components: (i) the physical entities, (ii) the interactions among these entities, and (iii) the dynamics of these entities and interactions. The mechanisms that drive complex disease can be productively viewed in the context of the perturbations of these components. One challenge in this regard is to identify the pathways altered in specific diseases. To address this challenge, Gene Set Enrichment Analysis (GSEA) and others have been developed, which focus on alterations of individual properties of the entities (such as gene expression). However, the dynamics of the interactions with respect to disease have been less well studied (i.e., properties of components ii and iii).ResultsHere, we present a novel method called Gene Interaction Enrichment and Network Analysis (GIENA) to identify dysregulated gene interactions, i.e., pairs of genes whose relationships differ between disease and control. Four functions are defined to model the biologically relevant gene interactions of cooperation (sum of mRNA expression), competition (difference between mRNA expression), redundancy (maximum of expression), or dependency (minimum of expression) among the expression levels. The proposed framework identifies dysregulated interactions and pathways enriched in dysregulated interactions; points out interactions that are perturbed across pathways; and moreover, based on the biological annotation of each type of dysregulated interaction gives clues about the regulatory logic governing the systems level perturbation. We demonstrated the potential of GIENA using published datasets related to cancer.ConclusionsWe showed that GIENA identifies dysregulated pathways that are missed by traditional enrichment methods based on the individual gene properties and that use of traditional methods combined with GIENA provides coverage of the largest number of relevant pathways. In addition, using the interactions detected by GIENA, specific gene networks both within and across pathways associated with the relevant phenotypes are constructed and analyzed.

[1]  M E J Newman,et al.  Modularity and community structure in networks. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[3]  L. Hood,et al.  Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas , 2007, Proceedings of the National Academy of Sciences.

[4]  Hiroyuki Mano,et al.  Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells , 2005, Cancer science.

[5]  David Warde-Farley,et al.  Dynamic modularity in protein interaction networks predicts breast cancer outcome , 2009, Nature Biotechnology.

[6]  Zoltan Szallasi,et al.  Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer , 2010, Nature Medicine.

[7]  A. G. de la Fuente.  From 'differential expression' to 'differential networking' - identification of dysfunctional regulatory networks in diseases. , 2010, Trends in genetics : TIG.

[8]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Mian Wu,et al.  p53 and Bad: remote strangers become close friends , 2007, Cell Research.

[10]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Trey Ideker,et al.  Integrating physical and genetic maps: from genomes to interaction networks , 2007, Nature Reviews Genetics.

[12]  Donald Geman,et al.  Merging microarray data from separate breast cancer studies provides a robust prognostic test , 2008, BMC Bioinformatics.

[13]  Donald Geman,et al.  Relative expression analysis for identifying perturbed pathways , 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[14]  T. Ideker,et al.  Network-based classification of breast cancer metastasis , 2007, Molecular systems biology.

[15]  B. Clurman,et al.  FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation , 2008, Nature Reviews Cancer.

[16]  J. Bartek,et al.  Order from Destruction , 2001, Science.

[17]  Salim A. Chowdhury,et al.  Subnetwork State Functions Define Dysregulated Subnetworks in Cancer , 2010, J. Comput. Biol..

[18]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[19]  Donald Geman,et al.  Identifying Tightly Regulated and Variably Expressed Networks by Differential Rank Conservation (DIRAC) , 2010, PLoS Comput. Biol..

[20]  A E Giuliano,et al.  Accumulation of Glucosylceramides in Multidrug-resistant Cancer Cells* , 1996, The Journal of Biological Chemistry.

[21]  L. Kirshenbaum,et al.  p53 activates the mitochondrial death pathway and apoptosis of ventricular myocytes independent of de novo gene transcription. , 2001, Journal of molecular and cellular cardiology.

[22]  Edward R. Dougherty,et al.  A CoD-based reduction algorithm for designing stationary control policies on Boolean networks , 2010, Bioinform..

[23]  H. Dressman,et al.  Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. , 2008, JAMA.

[24]  Lurong Zhang,et al.  Tachyplesin activates the classic complement pathway to kill tumor cells. , 2005, Cancer research.

[25]  Jean-Marc Guinebretière,et al.  Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients , 2011, BMC Cancer.

[26]  Tian Zheng,et al.  Identification of gene interactions associated with disease from gene expression data using synergy networks , 2008, BMC Systems Biology.

[27]  Gary D Bader,et al.  The Genetic Landscape of a Cell , 2010, Science.

[28]  R. Tibshirani,et al.  On testing the significance of sets of genes , 2006, math/0610667.

[29]  Yu Liu,et al.  Systems Biology Analyses of Gene Expression and Genome Wide Association Study Data in Obstructive Sleep Apnea , 2011, Pacific Symposium on Biocomputing.

[30]  Simone Sanna-Cherchi,et al.  Scara5 is a ferritin receptor mediating non-transferrin iron delivery. , 2009, Developmental cell.

[31]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[32]  C. Elston,et al.  The assessment of histological differentiation in breast cancer. , 1985, The Australian and New Zealand journal of surgery.

[33]  I. Pollack,et al.  AG490 influences UCN-01-induced cytotoxicity in glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation. , 2007, Cancer letters.

[34]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[35]  F. McCormick,et al.  Cancer targets in the Ras pathway. , 2005, Cold Spring Harbor symposia on quantitative biology.

[36]  R. Sharan,et al.  Expander: from expression microarrays to networks and functions , 2010, Nature Protocols.

[37]  P. Donnelly,et al.  Genome-wide strategies for detecting multiple loci that influence complex diseases , 2005, Nature Genetics.

[38]  M. Oren,et al.  Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F , 2005, Cell Death and Differentiation.

[39]  Hsiao-Huei Wu,et al.  MDM2--master regulator of the p53 tumor suppressor protein. , 2000, Gene.

[40]  P. Steeg,et al.  Cancer prognostics: Past, present and p27 , 1997, Nature Medicine.

[41]  Jian Li,et al.  Identifying Gene Interaction Enrichment for Gene Expression Data , 2009, PloS one.

[42]  U. Moll,et al.  The mitochondrial p53 pathway. , 2009, Biochimica et biophysica acta.

[43]  Jialin Liu,et al.  The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. , 2010, Oncology reports.

[44]  Kohjiro Ueki,et al.  Molecular Balance between the Regulatory and Catalytic Subunits of Phosphoinositide 3-Kinase Regulates Cell Signaling and Survival , 2002, Molecular and Cellular Biology.